Scarica l'app Stockscreener
50.15
1.01%
0.50
Pre-mercato:
50.84
0.69
+1.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$49.65
Aprire:
$49.75
Volume 24 ore:
1.54M
Relative Volume:
0.56
Capitalizzazione di mercato:
$12.61B
Reddito:
$2.32B
Utile/perdita netta:
$782.57M
Rapporto P/E:
18.01
EPS:
2.7838
Flusso di cassa netto:
$875.84M
1 W Prestazione:
+0.04%
1M Prestazione:
+7.04%
6M Prestazione:
+17.97%
1 anno Prestazione:
+17.01%
Intervallo 1D:
$49.51
$50.33
Intervallo di 1 settimana:
$48.21
$50.53
Portata 52W:
$33.76
$51.63
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
50.15 | 12.48B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Avoiding Lag: Real-Time Signals in (EXEL) Movement - Stock Traders Daily
Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL) - Seeking Alpha
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 - Investing.com India
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near - Yahoo Finance
Insider Sell: Patrick Haley Sells 32,110 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 By Investing.com - Investing.com South Africa
Exelixis EVP, Commercial Sold Shares Worth Over $1.5M - TradingView
Exelixis (EXEL) EVP Haley sells 32,110 shares, retains 357,638 - Stock Titan
Exelixis (EXEL): 12 Best Low Priced Growth Stocks to Invest In Now - Insider Monkey
How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration - Sahm
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types - BioSpace
Exelixis Inc stock (US30161Q1040): oncology player in focus after latest earnings and pipeline updat - AD HOC NEWS
Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration - Yahoo Finance
EXEL News | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha? - Trefis
EXEL (EXEL) Rule 144 filing: 32,110 issuer-held shares vested - Stock Titan
EXEL: Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy - TradingView
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView
Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing - Moomoo
Exelixis EVP and CFO Senner sells $1.75m in company stock By Investing.com - Investing.com South Africa
Exelixis EVP and CFO Senner sells $1.75m in company stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock By Investing.com - Investing.com South Africa
Exelixis (NASDAQ: EXEL) CEO reports share gifts and tax withholding - Stock Titan
Exelixis (NASDAQ: EXEL) CFO sells shares, reports tax withholding and large remaining stake - Stock Titan
Exelixis (EXEL) EVP reports 33,265-share tax withholding, 389,748-share stake - Stock Titan
Insider sale: Exelixis (EXEL) SVP and General Counsel sells 6,625 shares - Stock Titan
Exelixis (NASDAQ: EXEL) EVP Dana Aftab reports tax-withholding of 30,578 shares - Stock Titan
Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial - Moomoo
Exelixis partners with Merck for colorectal cancer trial By Investing.com - Investing.com South Africa
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer - BioSpace
Merck (MRK) Partners with Exelixis in Clinical Trial for Colorec - GuruFocus
Exelixis partners with Merck for colorectal cancer trial - Investing.com
EXEL Stock Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Proposed resale of vested restricted shares by EXEL (NASDAQ: EXEL) - Stock Titan
[144] EXELIXIS, INC. SEC Filing - Stock Titan
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Prospects Amidst Analyst Divergence - DirectorsTalk Interviews
Exelixis, Inc.Common Stock (NQ: EXEL - The Chronicle-Journal
Stephens Investment Management Group LLC Buys 28,265 Shares of Exelixis, Inc. $EXEL - MarketBeat
Thrivent Financial for Lutherans Increases Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus - AD HOC NEWS
Prediction: This stock could double by 2031 - MSN
48,292 Shares in Exelixis, Inc. $EXEL Purchased by Convergence Investment Partners LLC - MarketBeat
Prediction: This Stock Could Double By 2031 - Yahoo Finance
Prediction: This Stock Could Double By 2031 - The Motley Fool
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Arbejdsmarkedets Tillaegspension Acquires Shares of 555,504 Exelixis, Inc. $EXEL - MarketBeat
Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):